Welcome new legislation has the potential to further mental health research and improve patient care.

A review considers the question of which of 2 agents provides the most benefit, and best value, when single-agent therapy of depression is insufficient.

American Psychiatric Association president Dr. Jeffrey Lieberman discusses 2 new reports reflecting the bleak state of biomedical research funding in the United States.

Researchers test the effectiveness of guided, parent-provided cognitive-behavioral therapy for childhood anxiety.

A manual-based coping strategy proves effective in reducing depression and anxiety symptoms in those who provide care for family members with dementia.

A look at the FDA's recent and controversial opioid analgesic approval.

Dr. Atul Gawande talks with Dr. Eric Topol about being mesmerized by surgery, unpeeling great stories, and why he keeps his options open.

APA president Dr. Jeffrey Lieberman on how mental health parity and healthcare reform might affect the field of psychiatry.

A 29-year-old Stanford dropout has developed a new biotechnology that threatens to give laboratory medicine its biggest shakeup in decades.

This meta-analysis found differences in some side effects, but does that justify the price?